| Size | Price | Stock | Qty |
|---|---|---|---|
| 500mg |
|
||
| 1g |
|
||
| 2g |
|
||
| 5g | |||
| Other Sizes |
| Targets |
β-lactam
Cefalothin sodium, like other β-lactam antibiotics, exerts its antibacterial activity by binding to and inactivating penicillin-binding proteins (PBPs) located on the inner membrane of the bacterial cell wall. This binding inhibits the transpeptidase activity of PBPs, preventing the cross-linking of peptidoglycan chains, which is essential for bacterial cell wall integrity. This leads to cell lysis and bacterial death. |
|---|---|
| ln Vitro |
Cefalothin sodium is a potent β-lactam cephalosporin antibiotic agent with a wide range antibacterial activity against Gram-positive and Gram-negative bacteria. It inhibits the growth of various Gram-positive and Gram-negative bacteria, including several strains of S. pyogenes, S. aureus, and C. tetani. Its in vitro activity is consistent with its mechanism of inhibiting bacterial cell wall synthesis.
|
| ln Vivo |
Cefalothin sodium is administered parenterally and is used to prevent infection during surgery and to treat many kinds of infections of the blood, bone, or joint. It is also used to treat respiratory, biliary, and urinary tract infections, as well as meningitis, endocarditis, sepsis, tonsillitis, osteomyelitis, and scarlet fever. Its in vivo efficacy is established through its clinical use.
|
| Enzyme Assay |
Cefalothin sodium's antibacterial activity is assessed using standard in vitro microbiological susceptibility testing methods. Minimum inhibitory concentration (MIC) determinations are performed against various bacterial strains. The compound's binding affinity to penicillin-binding proteins (PBPs) can be evaluated using competitive binding assays.
|
| Cell Assay |
Cellular assays for cefalothin sodium are conducted using standard microbiological techniques with bacterial cultures. The compound's antibacterial activity is evaluated by determining the minimum inhibitory concentration (MIC) against various bacterial strains. Bacterial growth inhibition is assessed by measuring optical density or by counting colony-forming units.
|
| Animal Protocol |
In vivo animal model protocols for cefalothin sodium would involve its parenteral administration to animal models of infection to evaluate its efficacy. Studies may include models of surgical site infections, bacteremia, bone and joint infections, and respiratory tract infections.
|
| ADME/Pharmacokinetics |
Cefalothin sodium is administered parenterally. It has a molecular weight of 396.44 and a molecular formula of C16H15N2NaO6S2. Specific pharmacokinetic data is not extensively detailed in the available literature. It is a first-generation cephalosporin.
|
| Toxicity/Toxicokinetics |
Cefalothin sodium is generally well-tolerated as a cephalosporin antibiotic. Common adverse effects associated with cephalosporins include gastrointestinal disturbances, hypersensitivity reactions (particularly in patients with penicillin allergy), and local reactions at the injection site.
|
| References | |
| Additional Infomation |
Cefalotin sodium is an organic sodium salt containing the Cefalotin molecule. Cefalotin sodium is the sodium salt form of Cefalotin, a semi-synthetic β-lactam first-generation cephalosporin antibiotic with bactericidal activity. Cefalotin binds to and inactivates penicillin-binding protein (PBP) located on the inner membrane of the bacterial cell wall. PBP is involved in the final stages of bacterial cell wall assembly and cell wall remodeling during cell division. Inactivation of PBP interferes with the cross-linking of peptidoglycan chains, which is crucial for maintaining the strength and rigidity of the bacterial cell wall. This leads to weakening of the bacterial cell wall, ultimately resulting in cell lysis. Cefalotin is a cephalosporin antibiotic.
Cefalothin sodium (CAS# 58-71-9) is a first-generation cephalosporin antibiotic administered parenterally. It has a wide range of antibacterial activity against Gram-positive and Gram-negative bacteria. It is used to prevent infection during surgery and to treat various infections. |
| Molecular Formula |
C16H15N2NAO6S2
|
|---|---|
| Molecular Weight |
418.4138
|
| Exact Mass |
418.026
|
| Elemental Analysis |
C, 45.93; H, 3.61; N, 6.70; Na, 5.49; O, 22.94; S, 15.32
|
| CAS # |
58-71-9
|
| Related CAS # |
Cephalothin;153-61-7
|
| PubChem CID |
23675321
|
| Appearance |
Solid powder
|
| Boiling Point |
757.2ºC at 760 mmHg
|
| Melting Point |
240°C
|
| Flash Point |
411.8ºC
|
| Hydrogen Bond Donor Count |
1
|
| Hydrogen Bond Acceptor Count |
8
|
| Rotatable Bond Count |
7
|
| Heavy Atom Count |
27
|
| Complexity |
686
|
| Defined Atom Stereocenter Count |
2
|
| SMILES |
S1C([H])([H])C(C([H])([H])OC(C([H])([H])[H])=O)=C(C(=O)[O-])N2C([C@]([H])([C@@]12[H])N([H])C(C([H])([H])C1=C([H])C([H])=C([H])S1)=O)=O.[Na+]
|
| InChi Key |
VUFGUVLLDPOSBC-XRZFDKQNSA-M
|
| InChi Code |
InChI=1S/C16H16N2O6S2.Na/c1-8(19)24-6-9-7-26-15-12(14(21)18(15)13(9)16(22)23)17-11(20)5-10-3-2-4-25-10;/h2-4,12,15H,5-7H2,1H3,(H,17,20)(H,22,23);/q;+1/p-1/t12-,15-;/m1./s1
|
| Chemical Name |
(6R)-3-[(acetyloxy)methyl]-8-oxo-7R-[[2-(2-thienyl)acetyl]amino]-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid, monosodium salt
|
| Synonyms |
38253; Keflin; Lilly 38253
|
| HS Tariff Code |
2934.99.03.00
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: Please store this product in a sealed and protected environment, avoid exposure to moisture. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
H2O : 50~83 mg/mL (~119.50 mM; 超声助溶)
DMSO : 10 ~50 mg/mL (23.89 ~119.50 mM） |
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (5.97 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.5 mg/mL (5.97 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: 10% DMSO+40% PEG300+5% Tween-80+45% Saline: ≥ 2.5 mg/mL (5.97 mM) Solubility in Formulation 4: 50 mg/mL (119.50 mM) in PBS (add these co-solvents sequentially from left to right, and one by one), clear solution; with ultrasonication. |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.3900 mL | 11.9500 mL | 23.9000 mL | |
| 5 mM | 0.4780 mL | 2.3900 mL | 4.7800 mL | |
| 10 mM | 0.2390 mL | 1.1950 mL | 2.3900 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
|
|
|
|
|
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
